Vellgus Red Light Team

Demodex mites are microscopic arachnids that naturally inhabit human skin, but in cases of overpopulation, they become pathogenic, causing a range of dermatological and ophthalmological conditions. The most common clinical manifestations include Demodex-associated blepharitis (DAB) and rosacea. With traditional treatments…

Cutaneous Larva Migrans (CLM) represents one of the most frequently diagnosed dermatologic conditions in returning travelers from tropical and subtropical regions . While standard pharmacological protocols—primarily involving oral ivermectin and albendazole—remain the cornerstone of evidence-based management, emerging research into photobiomodulation (PBM),…

Pubic lice (Pthirus pubis), commonly known as “crabs,” are tiny parasitic insects that infest coarse body hair and feed on human blood. As interest grows in alternative and adjunctive therapies, some patients inquire about red light therapy for this condition.…

The management of scabies infestations presents significant clinical challenges, including treatment resistance, post-scabietic pruritus, and the burden of secondary infections. While photobiomodulation—commonly known as red light therapy—has demonstrated therapeutic potential across numerous dermatological conditions, questions remain regarding its specific role…

Head lice infestation (pediculosis capitis) remains a pervasive global public health concern, particularly among school-aged children. With an estimated prevalence of 19% among this demographic and the capacity for a single female louse to lay up to ten eggs daily,…

Primary Amoebic Meningoencephalitis (PAM), caused by the free-living amoeba Naegleria fowleri, represents one of the most devastating and rapidly fatal infections known to medicine. Often referred to as the “brain-eating amoeba,” it is found in warm freshwater environments and enters the…

Babesia, a malaria-like parasitic infection transmitted by ticks, presents a formidable challenge in the realm of vector-borne diseases. Unlike Lyme disease, which is caused by a bacterium, Babesia invades red blood cells, leading to a complex array of symptoms including…

Trypanosoma cruzi, the protozoan parasite responsible for Chagas disease, remains a significant public health challenge, affecting an estimated 6 to 7 million people worldwide . Current chemotherapeutic options, primarily benznidazole and nifurtimox, are associated with substantial toxicity and variable efficacy, particularly…

Cutaneous leishmaniasis (CL) remains a neglected parasitic disease with significant global morbidity, particularly in endemic regions across South America, Asia, and Africa. Conventional treatments, including pentavalent antimonials and miltefosine, present challenges ranging from parenteral administration and toxicity to emerging drug…

Trichomonas vaginalis infection remains the most prevalent non-viral sexually transmitted infection worldwide, with approximately 156 million new cases annually. While nitroimidazoles such as metronidazole represent the current standard of care, emerging resistance and treatment-associated adverse effects have created an urgent need…